⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ANVS News
Annovis Bio, Inc.
Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
ASMB
IONS
BIIB
ALT
TEVA
ANVS
SUPN
ABBV
AVXL
MRK
KAR
VNDA
Annovis to Host Corporate Update Webinar on September 2, 2026
globenewswire.com
ANVS
Form 8-K
sec.gov
ANVS
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
globenewswire.com
ANVS
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight
globenewswire.com
ANVS
SUPN
ABBV
VNDA
JAZZ
ACAD
MRK
Form 8-K
sec.gov
ANVS
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
globenewswire.com
ANVS
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
globenewswire.com
ANVS
Form 8-K
sec.gov
ANVS